Chesley Taft & Associates LLC held its position in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,845 shares of the medical instruments supplier’s stock at the end of the second quarter. Chesley Taft & Associates LLC’s holdings in Becton, Dickinson and were worth $945,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. North Star Investment Management Corp. raised its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the period. Crestwood Advisors Group LLC purchased a new position in shares of Becton, Dickinson and during the first quarter valued at $101,000. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and during the first quarter valued at $105,000. Parkside Financial Bank & Trust raised its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the period. Finally, Financial Architects Inc raised its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares during the period. 87.41% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.23% during mid-day trading on Thursday, reaching $198.36. The company had a trading volume of 411,538 shares. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The company’s 50-day moving average is $200.05 and its 200 day moving average is $189.42. The stock has a market capitalization of $45.14 billion, a P/E ratio of 57.45 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 earnings per share. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

TRADEMARK VIOLATION NOTICE: “Chesley Taft & Associates LLC Has $945,000 Stake in Becton, Dickinson and Company (BDX)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/31/chesley-taft-associates-llc-has-945000-stake-in-becton-dickinson-and-company-bdx.html.

Several research analysts recently weighed in on the company. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $195.79.

In related news, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last three months, insiders sold 48,605 shares of company stock worth $9,718,986. 1.40% of the stock is currently owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.